Symbols

FENC

Fennec Pharmaceuticals·NASDAQ

--(--)

FENC fundamentals

FENC Q4 2025 Earnings

Fennec Pharmaceuticals (FENC) released its earnings on Mar 24, 2026: revenue was 13.77M (YoY +73.25%), missed estimates; EPS was -0.1699 (YoY -182.23%), missed estimates.

Revenue / YoY

13.77M

+73.25%

EPS / YoY

-0.1699

-182.23%

Report date

Mar 24, 2026

FENC Earnings Call Summary for Q4,2025

Record Sales Growth: 2025 net product sales up 50% to $44.6 million, Q4 2025 sales +75% YoY to $13.8 million.
Strong Program Performance: Fennec HEARS conversion rates up 70% in Q4, enabling 20,000+ AYA patients/day.
Exclusivity Secured: Cipla settlement delays generics until 2033, freeing $2M+ annually for growth.
Global Expansion: Norgine launches in Europe, Japan trials show no efficacy impact, targeting 8-10 European launches in 2026.
Cost Efficiency: 2026 operating expenses $50M, up 43%, with 60% spent in H1 to drive H2 growth.

Earnings

EPS

Revenue

Revenue & Expenses

FENC has released its 2025 Q3 earnings report, with revenue of 12.46M, reflecting a YoY change of 78.69%, and net profit of -638.00K, showing a YoY change of 88.88%. The Sankey diagram below clearly presents FENC's revenue sources and cost distribution.

Key Indicators

Fennec Pharmaceuticals (FENC) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Fennec Pharmaceuticals (FENC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Fennec Pharmaceuticals (FENC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Fennec Pharmaceuticals (FENC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown